The CRO page explicitly offers third-party clinical trial laboratory testing for pharmaceutical companies under drug GCP and ISO 15189, alongside diagnostics and IVD sales. Included as diversified with group financials.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY PRC Accounting Standards / consolidated
1,448,033,298.51
-30,746,454.09 Net income attributable to shareholders of the listed company
Consolidated group totals include diagnostic, research and other products/services; they are not CRO or central laboratory segment revenue.
Parent-attributable net income is a loss; the 71.90% year-over-year change reflects a narrowing loss. The PRC measure excluding nonrecurring items differs from net income excluding share-based payment effects; this table uses the former.
2026Q3 (YTD) · Reporting notes
Consolidated group totals include diagnostic, research and other products/services; they are not CRO or central laboratory segment revenue.
The 10,739.06% year-over-year change in parent-attributable results reflects a move to profit from a small loss in the corresponding 2025 period; it is not equivalent revenue growth.
Nonrecurring items totaled CNY 58,099,485.02, including CNY 35,600,404.90 in reversals of individually impaired receivables and CNY 23,055,337.58 from business disposals (pretax items). Parent-attributable earnings differ materially from the measure excluding nonrecurring items.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The current website offers not only IVD performance validation and medical-device clinical trials but also explicitly third-party laboratory testing for pharmaceutical clinical trials.
SZSE:301060; the 2025 annual report and latest 2026 report were read from original consolidated statements.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
PharmaBlock Sciences reported consolidated revenue of RMB1.634 billion, up 15.16%, and attributable net income of RMB151.2 million for the nine months ended September 30, 2026. Attributable net income rose 33.36%, while net cash from operations declined 53.75% over the same period. The quarterly filing is unaudited and covers the year-to-date period.
